Shares of Edgewise Therapeutics, Inc. (EWTX) surged 5.33% in the pre-market session on Friday, as analysts expressed optimism about the healthcare company's prospects.
Scotiabank initiated coverage on EWTX with an Outperform rating and a $50 price target, citing expectations of positive momentum for the company. The firm believes that Edgewise Therapeutics' pipeline and potential in the healthcare sector could drive significant growth in the future.
The positive analyst sentiment has boosted investor confidence in EWTX, leading to the stock's pre-market rally. As more analysts weigh in on the company, the market's outlook on Edgewise Therapeutics may continue to improve, potentially supporting further upward movement in the stock price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.